Gary S. Stetz, Director at Hepion Pharmaceuticals, Inc. (HEPA), bought 500,000 shares at $0.05 ($25K) on 2026-08-03, disclosed to the SEC on 2026-08-12.
Open-market purchase of $25k HEPA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| HEPA | BUY | 2026-04-27 | $50K | — | Filing → |
| BCBP | BUY | 2018-03-14 | $8K | — | Filing → |
| BCBP | BUY | 2017-10-25 | $26K | — | Filing → |